An Open-Label, Multicenter, Dose Escalation, Randomized, Phase I Study To Evaluate Safety, Pharmacokinetics, Pharmacodynamics, And Anti-Tumor Activity Of Ro7567132 As Single Agent And In Combination With Atezolizumab In Participants With Advanced And/Or Metastatic Solid Tumor
